There are 2867 resources available
796P - Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial
Presenter: Chuan-Liang Cui
Session: Poster session 03
1067P - Discovery of a new CD4+ T cell cluster that correlates PD-1 blockade efficacy
Presenter: Hiroshi Kagamu
Session: Poster session 15
1410P - Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Sumati Gupta
Session: Poster session 11
797P - Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm
Presenter: Irene Reijers
Session: Poster session 03
1068P - Predicting response to pembrolizumab in non-small cell lung cancer using spatial analysis of biopsy images by deep learning
Presenter: Efrat Ofek
Session: Poster session 15
1411P - Development and validation of a novel six-gene signature to accurately risk stratify men with early-stage prostate cancer to aid in treatment decision making
Presenter: Agnieszka Krzyzanowska
Session: Poster session 11
798P - NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis
Presenter: Jorja Braden
Session: Poster session 03
1069P - An immune-based score for the prediction of clinical outcome in patients with metastatic non-small cell lung cancer treated with first-line immunotherapy
Presenter: Andrea Sbrana
Session: Poster session 15
1412P - Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ravi Madan
Session: Poster session 11
799P - A pilot study of the neo-adjuvant use of vemurafenib plus cobimetinib in patients with BRAF mutant melanoma with palpable lymph node metastases
Presenter: Teresa Petrella
Session: Poster session 03